Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.42 |
| ▸ | NPC1 | O15118 | 8/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30845964 | 1.00 | RAB9A (0.42) | RAB9ANPC1KMT2AALDH1A1MAPK1 | |
| SCHEMBL1425108 | 0.83 | KDM4E (0.56) | RAB9ANPC1KMT2AALDH1A1MAPK1 | |
| SCHEMBL22467460 | 0.82 | RAB9A (0.44) | RAB9ANPC1KMT2AALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL29154171 | 0.82 | KDM4E (0.55) | RAB9ANPC1KMT2AALDH1A1MAPK1 | |
| SCHEMBL153746 | 0.82 | RAB9A (0.41) | RAB9ANPC1KMT2AALDH1A1MAPK1 | |
| SCHEMBL15094137 | 0.79 | MAPT (0.47) | RAB9ANPC1KMT2AALDH1A1MAPK1 | |
| SCHEMBL18348115 | 0.79 | KDM4A (0.42) | RAB9ANPC1KMT2AALDH1A1MAPK1 | |
| SCHEMBL31033036 | 0.79 | RAB9A (0.39) | RAB9ANPC1KMT2AALDH1A1MAPK1 | |
| SCHEMBL22912737 | 0.79 | RAB9A (0.46) | RAB9ANPC1KMT2AALDH1A1MAPK1 | |
| SCHEMBL30356976 | 0.79 | KDM4A (0.42) | RAB9ANPC1KMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4482587-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024020156-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023164063-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| EP-3326627-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | RAB9A 3984/4885NPC1 1319/4885KMT2A 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.